Gene · 2160
Papers2,705
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,705
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab in vitro. | Res Pract Thromb Haemost | 2025 | 40837022 | PubTator, text mining | PubMed |
| Clarification of fibrin generation and degradation reaction processes of clot-fibrinolysis waveform in hemorrhagic disorders. | PLoS One | 2025 | 40824945 | PubTator, text mining | PubMed |
| Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes. | Blood | 2025 | 40811855 | PubTator, text mining | PubMed |
| Factor XI levels and the risk of cardiovascular events: a systematic review and meta-analysis of case-control and cohort studies. | Res Pract Thromb Haemost | 2025 | 40756184 | PubTator, text mining | PubMed |
| The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII. | Commun Biol | 2025 | 40750828 | PubTator, text mining | PubMed |
| Molecular Aspects of Rare Coagulation Factor Deficiencies. | Cureus | 2025 | 40747195 | PubTator, text mining | PubMed |
| Influence of long-distance trail running on blood hemostasis at the World Mountain Trail Running Championship 2023-a pilot study. | Res Pract Thromb Haemost | 2025 | 40746438 | PubTator, text mining | PubMed |
| Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism in the direct oral anticoagulants era: Findings from the TULIPE registry. | PLoS One | 2025 | 40729349 | PubTator, text mining | PubMed |
| Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of venous thromboembolism. | Res Pract Thromb Haemost | 2025 | 40687386 | PubTator, text mining | PubMed |
| Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation. | J Thromb Haemost | 2025 | 40653090 | PubTator, text mining | PubMed |
| Structure and interactions of the proteins from the contact system. | Blood | 2025 | 40638675 | PubTator, text mining | PubMed |
| Altered co-expression patterns of synovial fluid proteins related to the immune system and extracellular matrix organization in late stage OA, compared to non-OA controls. | Front Immunol | 2025 | 40625747 | PubTator, text mining | PubMed |
| Proteome-wide Mendelian randomization and colocalization analysis identify therapeutic targets for stroke. | BMC Neurol | 2025 | 40596960 | PubTator, text mining | PubMed |
| Human Genetic Evidence Does Not Support a Causal Role for Reduced FXI Levels in Heart Failure Pathogenesis-Brief Report. | Arterioscler Thromb Vasc Biol | 2025 | 40567226 | PubTator, text mining | PubMed |
| Reducing Plasma Factor XI Concentration With siRNA Technology. | JACC Basic Transl Sci | 2025 | 40562492 | PubTator, text mining | PubMed |
| Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents. | J Thromb Haemost | 2025 | 40499719 | PubTator, text mining | PubMed |
Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis. | Res Pract Thromb Haemost | 2025 | 40496572 | PubTator, text mining | PubMed |
| DOAC-Stop reverses the anticoagulant effect of asundexian and milvexian. | J Thromb Haemost | 2025 | 40484204 | PubTator, text mining | PubMed |
| Factor XI inhibitors: is it time for a paradigm shift in anticoagulation? | J Cardiovasc Med (Hagerstown) | 2025 | 40472174 | PubTator, text mining | PubMed |
| Potential therapeutic targets for deep vein thrombosis: A proteome-wide Mendelian randomization study. | Phlebology | 2025 | 40462713 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2160/papers?page=7